IRIS
BERTOLI, ADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.642
EU - Europa 3.215
AS - Asia 3.146
SA - Sud America 472
AF - Africa 63
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 9
Totale 30.557
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.550
SG - Singapore 1.481
CN - Cina 633
IT - Italia 522
DE - Germania 429
BR - Brasile 388
RU - Federazione Russa 379
SE - Svezia 333
UA - Ucraina 295
HK - Hong Kong 268
PL - Polonia 257
FR - Francia 247
VN - Vietnam 234
IE - Irlanda 226
KR - Corea 226
FI - Finlandia 198
GB - Regno Unito 163
JP - Giappone 80
NL - Olanda 48
CA - Canada 46
IN - India 43
MX - Messico 33
AR - Argentina 28
ID - Indonesia 24
BD - Bangladesh 23
AT - Austria 22
ES - Italia 21
ZA - Sudafrica 21
CZ - Repubblica Ceca 20
IQ - Iraq 20
TR - Turchia 20
BE - Belgio 14
CL - Cile 13
UZ - Uzbekistan 13
CH - Svizzera 11
PH - Filippine 11
VE - Venezuela 10
AU - Australia 9
CO - Colombia 9
JO - Giordania 9
PK - Pakistan 9
EC - Ecuador 8
EG - Egitto 8
IL - Israele 8
PY - Paraguay 8
KE - Kenya 7
KG - Kirghizistan 7
DK - Danimarca 6
ET - Etiopia 6
EU - Europa 6
JM - Giamaica 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
IR - Iran 4
PE - Perù 4
RO - Romania 4
SA - Arabia Saudita 4
BG - Bulgaria 3
DZ - Algeria 3
LT - Lituania 3
NP - Nepal 3
PT - Portogallo 3
TN - Tunisia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AZ - Azerbaigian 2
BO - Bolivia 2
CY - Cipro 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
KZ - Kazakistan 2
LY - Libia 2
MN - Mongolia 2
NG - Nigeria 2
OM - Oman 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AO - Angola 1
BW - Botswana 1
BY - Bielorussia 1
CM - Camerun 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
LB - Libano 1
LK - Sri Lanka 1
MK - Macedonia 1
MT - Malta 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SI - Slovenia 1
Totale 30.555
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.679
Wilmington 6.056
Houston 4.714
Singapore 910
Fairfield 714
Chandler 589
Ann Arbor 528
Ashburn 464
San Jose 367
Seattle 303
Hong Kong 263
Beijing 256
Jacksonville 242
Kraków 231
Cambridge 229
Rome 214
Dublin 210
Medford 156
New York 150
Santa Clara 132
Council Bluffs 127
Helsinki 123
Dearborn 112
Los Angeles 107
The Dalles 93
Zhengzhou 76
Lawrence 73
Tokyo 71
Hanoi 68
Ho Chi Minh City 61
Milan 57
Moscow 56
San Diego 55
Munich 46
São Paulo 42
Dallas 41
Lauterbourg 41
Buffalo 39
Menlo Park 36
Mülheim 35
Orem 35
Nuremberg 31
London 25
Palo Alto 25
San Francisco 25
Phoenix 23
Montreal 22
Warsaw 21
Creede 20
Boardman 19
Jakarta 19
Redondo Beach 18
Chennai 17
Colorado Springs 17
Brooklyn 16
Chicago 16
Denver 16
Falls Church 16
Shanghai 16
Atlanta 15
Stockholm 15
University Park 15
Amsterdam 14
Frankfurt am Main 14
Guangzhou 14
Nanjing 14
Olomouc 14
Brussels 13
Lappeenranta 12
Rio de Janeiro 12
Boston 11
Columbus 11
Haiphong 11
Johannesburg 11
North Bergen 11
Norwalk 11
Bari 10
Tashkent 10
Amman 9
Belo Horizonte 9
Dong Ket 9
Salvador 9
Vienna 9
Manchester 8
Redwood City 8
Vancouver 8
Verona 8
Baghdad 7
Da Nang 7
Hefei 7
Jinan 7
Mexico City 7
Mountain View 7
Nairobi 7
Seoul 7
Biên Hòa 6
Brno 6
City of London 6
Dhaka 6
Kunming 6
Totale 25.564
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 533
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 525
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 505
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 504
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 503
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 491
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 490
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 487
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 483
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 478
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 477
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 472
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 472
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 471
Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster 471
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 468
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 467
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 466
A case of Italian HIV-2 infection: a genetic analysis 460
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 457
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 456
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 455
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 452
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 450
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 447
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 438
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 434
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 432
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 431
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 431
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 426
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 426
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 422
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 421
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 421
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 420
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 416
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 416
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 415
The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages 415
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 413
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 411
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 409
Temporal change in the use of genotypic resistance testing over the years 1999--2003 405
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 395
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome 392
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 392
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 391
Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART 381
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 379
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 376
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 376
HIV-1 non-B subtypes in Italy: a growing trend 375
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 371
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 359
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 358
null 357
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 356
Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 354
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 353
The V118I mutation as a marker of advanced HIV infection and disease progression 350
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 316
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 302
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 262
HIV MDR is still a relevant issue despite its dramatic drop over the years 237
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 172
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 170
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 157
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 152
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 151
An HIV Type 2 Case Series in Italy: A Phylogenetic Analysis 137
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 135
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 134
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 133
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 123
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 121
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 111
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 100
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 100
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 90
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 84
Infection Rate of Respiratory Viruses in the Pandemic SARS-CoV-2 Period Considering Symptomatic Patients: Two Years of Ongoing Observations 83
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings 80
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 74
Genetic heterogenicity of HIV-1 protease in drug-naive and drug-treated HIV-positive patients 74
Factors predictive of multinucleoside analogue-resistance mutations in an unselected cohort of HAART-failed patients. 71
Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes 70
Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches 63
Cross-resistance among NNRTIs: evaluation of the option of recycling Efavirenz after Nevirapine failure 63
Factors predictive of virological response after genotyping resistance test (GRT): data from an unselected cohort 62
Identification of the Minimal Conserved Structure of the HIV-Reverse Transcriptase under the Presence and Absence of Drug Pressure 50
Temporal characterization of frequency of drug-resistance associated mutations in the HIV-1 protease and reverse transcriptase 42
Time to detection and loss of M184 genotypic mutation among HIV patients treated with 3TC and failing an HAART regimen 41
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation 40
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 17
A high degree of genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity. 15
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 15
An increased genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity 15
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing 14
Totale 30.910
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.219
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.219
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021262 0 0 0 0 0 0 0 0 0 77 128 57
2021/20221.111 59 77 106 65 33 88 46 40 207 81 44 265
2022/20231.445 119 136 113 186 104 288 87 138 117 47 76 34
2023/2024437 57 10 30 20 45 98 22 20 10 20 5 100
2024/20252.321 92 501 243 116 99 132 299 120 258 134 152 175
2025/20263.746 315 149 399 386 391 177 577 508 506 338 0 0
Totale 30.930